Many biotech executives believe their internal IT team “owns security,” so the company is covered. That sounds responsible, it even sounds like a logical argument. However, in most cases…it is the opposite.
Ownership without staffing, funding, response authority, and around-the-clock operating capacity is not a security strategy. It is an executive expectation placed on a team that was never built to meet it.
For biotech companies under $100 million in revenue, the business often grows faster than its security operating model. Employees, cloud platforms, laboratory systems, contractors, and sensitive research expand while responsibility remains concentrated in a small team.
Leadership then asks that team to maintain 24×7 vigilance while also running the company’s technology environment.
That is not efficiency. It is unmanaged exposure.
The Internal Team Is Not the Problem
Directors of IT and security leaders are often blamed when monitoring gaps appear. In reality, many are operating inside an impossible model.
A small team may own the IT infrastructure, cloud administration, identity access management, endpoints, vendors, audits, backups, user requests, projects, and incident response. Even capable people cannot maintain continuous investigation coverage without sacrificing something else.
After-hours responsibility usually falls to an informal on-call rotation. That creates predictable weaknesses.
The person on call may not be a security analyst. Alerts may arrive without context. Escalation may be incomplete. Employees may hesitate to isolate a device or disable an executive account without approval. How would you feel waking up at 2am on a Christmas morning?
The company believes it has a response model because someone carries a phone.
A phone is not a SOC.
Why This Matters More in Biotech
Biotech companies do not operate like ordinary professional-services firms.
Research may continue outside normal business hours. Cloud collaboration may involve scientists, contractors, universities, partners, and external laboratories. Intellectual property may be distributed across endpoints, cloud repositories, collaboration tools, and laboratory environments.
A compromised account can expose valuable research without causing an obvious outage. A vendor credential can create a path into poorly monitored systems. Malware can interrupt research at a critical point in a study.
When the response model is underfunded, the threat is given time.
Time allows an attacker to explore, escalate privileges, collect information, and move laterally. By the time leadership becomes involved, the company may be unable to answer what happened, what was accessed, and how long the activity continued.
That uncertainty can damage investor confidence even when the technical incident appears limited.
The Cost of Building a Real Internal Capability
Some executives believe the answer is to build an internal SOC.
That may be appropriate for a large, mature organization. It is often unrealistic for a biotech company under $100 million in annual revenue.
A functioning internal capability requires more than one analyst. Continuous coverage requires multiple shifts, time-off coverage, training, quality control, escalation, leadership, security stack, threat intelligence, runbooks, case management, reporting, and engineering support.
Hiring one person does not create 24×7 coverage. It creates one more person who can be unavailable.
Challenge any proposal claiming round-the-clock operations can be created by adding one employee or assigning more work to the existing team.
The correct financial comparison is not one salary versus a managed service fee. It is the total cost of building and maintaining the capability the business actually requires.
What a Managed or Co-Managed Model Should Deliver
Managed security should not be evaluated as a collection of tools. The value is in the operating commitments.
A credible model should provide 24/7 monitoring, experienced analysts, documented escalation, investigation depth, and measurable response expectations. Critical alerts should have acknowledgement and investigation targets, such as 15 or 30 minutes, rather than vague promises of “24×7 monitoring.”
The provider should also understand its authority.
Can it isolate an endpoint immediately? Disable a compromised account? Block a malicious connection? Must it wait for approval? Who is contacted if the primary escalation owner is unavailable?
These decisions should be made before an incident, not during one.
In a co-managed model, the provider maintains continuous coverage and investigation while the internal team supplies business context and manages organizational priorities. This reduces pressure without removing authority.
That is what makes managed security a strategic operating model rather than a staffing shortcut.
Practical Decision Criteria for Leadership
Executives should evaluate the current model against practical standards.
Coverage must be continuous and provable. “Someone checks alerts” is not enough.
Response times must be defined. Leadership should know how quickly critical alerts are acknowledged, investigated, and escalated.
Visibility should extend across identity, endpoint, cloud, network, backups, and third-party access.
Containment authority must be explicit. Delayed approval can turn a manageable event into a business disruption.
The service should support the internal team rather than overwhelm it with raw alerts and incomplete cases.
Reporting should show recurring weaknesses, response performance, and unresolved risk.
Finally, the model must scale. A process that barely works today will not support additional research programs, partnerships, employees, and cloud services.
The Question Leadership Should Stop Avoiding
The uncomfortable question is not whether the internal team works hard enough.
It is whether leadership has funded the capacity required for the responsibility it assigned.
If the company expects continuous monitoring, fast investigation, reliable escalation, and immediate containment, those capabilities must exist as an operating system, not as an assumption.
A security assessment can expose whether the current environment has adequate visibility, after-hours response, containment authority, backup readiness, vulnerability management, and incident-response discipline. It can also show where internal ownership should remain and where managed capacity is necessary.
The goal is not to outsource accountability.
The goal is to stop pretending accountability exists without capacity.
As the company grows, leadership must decide whether the security model will grow with it or whether the business will continue depending on an underfunded team to carry a responsibility it was never equipped to support.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
Biotech Podcast
On this podcast, we discuss data recovery. This episode explores the significant challenges biotech firms face in developing effective data recovery strategies. Topics include the importance of regular testing, rapid restoration capabilities, and the risks of inadequate planning. It highlights how speed and efficiency are crucial to uninterrupted operations, regulatory compliance, and maintaining trust in a data-driven industry. Tune in to the discussion.
Biotech YouTube
Subscribe to our YouTube channel. On a recent episode,” The Delay That Destroys Biotech”, Most biotech breaches aren’t discovered for months. And by the time they are, the damage is already done. In this episode, we break down what really happens during that silent window and why detection time, not prevention, defines your risk. If you can’t see it early, you can’t control it.
